0 results available. Select is focused ,type to refine list, press Down to open the menu,
No data available
No data available
No data available
Five-year compound annual growth rate in unadjusted EBIT.
Unadjusted EBIT CAGR (5y) measures the five-year compound annual growth rate in Unadjusted EBIT.
Compound annual growth rate (CAGR) is a commonly used business and investing term that measures the growth of a metric over multiple periods. CAGRs are useful since they reduce the effect of volatility in specific periods, unlike arithmetic means.
You can find the calculation details for GSK’s Unadjusted EBIT CAGR outlined below. The calculation starts by listing values for Unadjusted EBIT for the last six fiscal years that are required to calculate CAGR:
| Fiscal Year | Unadjusted EBIT | YoY Growth |
|---|---|---|
| 2019-12-31T00:00:00.000Z | 6.957 B | |
| 2020-12-31T00:00:00.000Z | 5.979 B | −14.1% |
| 2021-12-31T00:00:00.000Z | 4.321 B | −27.7% |
| 2022-12-31T00:00:00.000Z | 6.433 B | 48.9% |
| 2023-12-31T00:00:00.000Z | 6.746 B | 4.9% |
| 2024-12-31T00:00:00.000Z | 4.027 B | −40.3% |
Using the values for Unadjusted EBIT listed in the table above, we can calculate three-year Unadjusted EBIT CAGR as follows:
Number of years = 5
Multiplier = £4.027 B / £6.957 B = 0.58
5 Year CAGR = 0.58 ^ (1/5) - 1 = −10.4%
Growth calculations are always made in the company’s reporting currency to ensure currency fluctuations do not impact the calculation. GSK’s reports in the GBP currency. You can read more about Unadjusted EBIT here and compound annual growth rate on Wikipedia. You may also find variants three-year Unadjusted EBIT CAGR, and seven-year Unadjusted EBIT CAGR useful.
No data available